Targeting CCR2 + macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.

Yutuan WuNicholas B JenningsYunjie SunSantosh K DasariEmine BayraktarSara CorvignoElaine SturDeanna GlassmanLingegowda S MangalaAdrian Lankenau AhumadaShannon N WestinAnil K SoodWei Hu

Published in: Journal of cancer research and clinical oncology (2022)

TAMs and enhancing the efficacy of AVA therapy in ovarian cancer.

Keyphrases

endothelial cells
vascular endothelial growth factor
immune response
mesenchymal stem cells
drug delivery
bone marrow